Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round
Executive Summary
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.
You may also be interested in...
Amgen Biosimilar For Stelara May Face Price Drop In Medicare Shortly After Launch; What’s A Follow-On To Do?
With J&J's Stelara set for Medicare negotiation, the fate of Amgen’s new ustekinumab interchangeable be a test case for concerns that the pricing program will significantly undercut incentives for developing biosimilars for blockbusters in the Medicare market.
Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe
A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”
Medicare Copay ‘Smoothing’ Plan Shows Nothing Is Simple In Part D
Guidance on how to implement a new policy to permit Part D beneficiaries to pay high copays in monthly installments (rather than all at once at the pharmacy counter) shows that there is no such thing as a straight-forward change in the drug benefit program.